Endpoints News

AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population

Published

2 weeks ago

on

AstraZeneca’s investigational antibody for chronic obstructive pulmonary disease has succeeded in two late-stage studies, despite having previously failed in a mid-stage trial. And, unexpectedly, the company revealed Friday the drug yielded positive data in a …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version